Stocks Health care ALT
NASDAQ · Health careAltimmune, Inc. (ALT)
It posted a net loss of $91.8M. In fiscal 2025 capital spending exceeded operating cash flow by $67.5M. At June 30, 2026 it held $63M in cash against $34.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Altimmune, Inc.
- Net worth
- Altimmune, Inc. has a market value (market cap) of $412.4M at the latest share price, and shareholders' equity of $474.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $41K (+105.0% year on year), with a net loss of $88.1M.
- Cash flow
- In fiscal 2025 operations used $67.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Altimmune, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Altimmune, Inc. does
Altimmune, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $41K | -$88.1M | -$1.00 | -$67.5M |
| 2024 | $20K | -$95.1M | -$1.34 | n/a |
| 2023 | $426K | -$88.4M | -$1.66 | -$75.9M |
| 2022 | -$68K | -$84.7M | -$1.81 | -$62.7M |
| 2021 | $4.4M | -$97.1M | -$2.35 | -$90.4M |
| 2020 | $8.2M | -$49M | -$1.91 | -$34.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALT ranks in Health care
Latest SEC filings
What Altimmune, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026New debt 8-K
- October 27, 2026
- September 29, 2026Executive or director change8-KAltimmune appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer.
- August 12, 2026
- August 12, 2026
- July 28, 2026
- June 16, 2026Other event 8-K
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 13, 2026
Insider trades
What the people running Altimmune, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $44.3K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Weaver Gregory LChief Financial Officer | Exercised options | 14,475 | - |
| October 1, 2026 | Weaver Gregory LChief Financial Officer | Shares withheld for tax | 4,379 | $12.1K |
| October 1, 2026 | Arbet-Engels ChristopheChief Medical Officer | Exercised options | 37,500 | - |
| October 1, 2026 | Arbet-Engels ChristopheChief Medical Officer | Shares withheld for tax | 12,679 | $35K |
| September 16, 2026 | Richardson Linda MChief Commercial Officer | Exercised options | 24,000 | - |
| September 16, 2026 | Richardson Linda MChief Commercial Officer | Shares withheld for tax | 6,826 | $22.1K |
| August 13, 2026 | Durso Jerome BenedictPresident and CEO, Director | Bought | 15,000 | $44.3K |
| July 31, 2026 | Weaver Gregory LChief Financial Officer | Received as pay | 1,753 | $4.2K |
Who owns ALT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Deep Track Capital, LP13G, passive with 3 related filers | 9.99% | April 30, 2026 |
| Chen Yu13G, passive with 4 related filers | 9.8% | May 1, 2026 |
| Viking Global Investors LP13G, passive with 9 related filers | 6.7% | May 1, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 6.5% | May 1, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 210 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 20,385,284 | +7,590,007 |
| Deep Track Capital, LP | 19,250,000 | new |
| State Street Corp | 12,098,540 | +4,952,990 |
| TCG Crossover Management, LLC | 10,000,000 | new |
| Vanguard Capital Management LLC | 8,177,752 | +2,519,703 |
| Vanguard Portfolio Management LLC | 7,330,265 | +1,948,263 |
| Marshall Wace, Llp | 6,841,055 | +2,823,154 |
| Viking Global Investors LP | 6,700,000 | new |
| RA Capital Management, L.P. | 6,500,000 | new |
| Geode Capital Management, LLC | 5,011,314 | +1,904,218 |
| Woodline Partners LP | 3,400,312 | new |
| Millennium Management LLC | 3,309,122 | +50,931 |
| Nantahala Capital Management, LLC | 3,000,000 | new |
| Trails Edge Capital Partners, LP | 2,660,000 | new |
| Nuveen, LLC | 2,405,354 | +70,753 |
| Two Sigma Investments, LP | 2,381,142 | -97,758 |
| Goldman Sachs Group Inc | 2,214,450 | +863,801 |
| Great Point Partners LLC | 1,741,232 | new |
| Northern Trust Corp | 1,599,226 | +602,505 |
| Weiss Asset Management LP | 1,530,803 | new |
Insiders
11 insiders reported holding 799,972 shares in total, about $1.7M at the last price.
| Holder | Shares |
|---|---|
| Garg Vipin KDirector | 424,519 |
| Roberts M ScotChief Scientific Officer | 113,699 |
| Jordt Raymond MChief Business Officer | 70,107 |
| Durso Jerome BenedictPresident and CEO, Director | 62,500 |
| Weaver Gregory LChief Financial Officer | 49,927 |
| Arbet-Engels ChristopheChief Medical Officer | 24,821 |
| Gill JohnDirector | 21,700 |
| Richardson Linda MChief Commercial Officer | 17,174 |
| Pisano WayneDirector | 13,498 |
| Sohn Catherine A.Director | 1,500 |
Questions about ALT
What does Altimmune, Inc. do?
Altimmune, Inc. is a company in the Health care sector, listed on NASDAQ as ALT. Its shares trade on NASDAQ under the ticker ALT.
What is Altimmune, Inc.'s net worth?
Altimmune, Inc. has a market value (market cap) of $412.4M at the latest share price, and shareholders' equity of $474.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Altimmune, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $91.8M.
When did Altimmune, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Altimmune, Inc.'s next earnings report?
Altimmune, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare ALT with
Follow ALT
Get an email when Altimmune, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Altimmune, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.